("EquiTech"), a biopharmaceutical development company currently focused on a fast absorbing ibuprofen as its lead compound, today announced that it has retained The Equicom Group Inc. (Equicom) to provide the Company with strategic investor relations and financial communications services.

Equicom provides financial communication services to leading Canadian companies and has proven expertise in technology industries. After careful analysis and due diligence, the Company believes that Equicom can best assist the Company in elevating its profile within the professional investment community. For its tailored investor relations package, EquiTech will pay Equicom a monthly retainer fee of $4,000. Equicom does not have any interest, directly or indirectly, in Equitech Corporation or its securities. The initial contract term is for 6 months. The principals of Equicom are Barry Hildred, President and Jason Hogan, Executive Vice President.

About Equicom

Based in the centre of Canada's investment/financial community, Toronto, Ontario, and supported by satellite offices in Montreal and Vancouver, The Equicom Group's core competency is the development and execution of tailored, strategic, financial communication programs. Equicom provides its clients with a comprehensive suite of services including: investor relations, media relations, annual report production, web development and web broadcasting. Equicom currently employs more than 30 professionals and works with more than 40 public companies. For further information, visit www.equicomgroup.com.

About Equitech Corporation

Equitech Corporation is a biopharmaceutical company with patent pending technology to create and develop better absorbing pharmaceutical products that are taken orally. EquiTech's lead compound is a fast absorbing ibuprofen for the treatment of moderate acute pain. EquiTech trades on the TSX Venture Exchange under the symbol EQT and has approximately 6 million common shares outstanding. For further information, visit www.equitechcorporation.com.

This news release shall not constitute an offer to sell or thesolicitation of an offer to buy the securities in any jurisdiction. The securities of the corporation have not been and will not be registered under the U.S. Securities Act, 1933, as amended and subject to certain exemptions may not be offered or sold in the United States or to U.S. persons. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This press release may contain forward-looking statements, i.e. information that is not strictly historical, concerning EquiTech's business and prospects. Forward-looking statements are subject to a number of risks and uncertainties. Actual events and results may differ materially from those discussed in this press release, due to factors including research, development, commercial and market risks.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

FOR FURTHER INFORMATION PLEASE CONTACT: